Agilis Robotics aims to raise funds before the first round of Phase B to be completed by 2022

Agilis Robotics aims to raise funds before the first round of Phase B to be completed by 2022

Successful testing in Vivo paves the way for the first human trial in the near future

Hong KongAnd the September 22 2022 /PRNewswire/- Agilis Robotics Limited (“Agilis Robotics“or the”a company‘), creator of the first surgical robotic tools in Hong Kong To target endoscopic submucosal dissection (ESD) and mass resection of bladder tumors (ERBT), he announced his fundraising status, as well as his latest technological achievements.

The Agilis Robotics fundraising round is complete in 2022, with preliminary round B to begin, which includes raising funds for related applications with the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) set to begin. These efforts will go towards improving the marketing efficiency of the company’s products in mainland China. Pre-Round B fundraising activity is expected to end by the end of 2022, with fundraising target set in 5 million US dollars. It should be noted that Agilis Robotics’ has targeted its market capitalization to meet the essential application requirements as stipulated in Chapter 18A relating to the listing of biotech companies on the Main Board of the Hong Kong Stock Exchange by 2025.

In the field of robotics, Agilis Robotics has made further progress in the areas of specification, compatibility, and artificial intelligence. On the spec front, its long, flexible and miniature robotic arms—with five degrees of freedom—enhanced tissue traction and hardware triangulation. Since the robotic arms also incorporate a variety of final effects, they can complete a wide range of complex tasks. Furthermore, seamless fit is achieved as each robotic arm has a diameter of less than 2.8 mm and can thus be directed directly through or in tandem with conventional endoscopes currently used in clinical practice. Regarding the usability of the surgeon, improvements have been made to the surgeon’s console, which is compact and mobile, allowing it to be placed closer to the patient. Moreover, with free-floating pen controls, smooth transition of endoscope controls can be achieved. Given the benefits and importance of AI-driven mentoring and training, Agilis Robotics has set performance standards to enhance user training and flatten the learning curve. This includes training in topics such as monocular depth estimation and instrumentation segmentation for conventional endoscopes.

Notably, Agilis Robotics has successfully completed in vivo tests, which included artificial cystectomy in June 2022. The extremely narrow diameter of the robotic arms allowed them to be compatible with conventional urological telescopes and wraps, and the arms were able to stabilize and cut tumor tissue. Importantly, the tumor was completely removed successfully. The company is now targeting first person trial/testing (FIM) in 2024.

Agilis Robotics has kept progress on the back of successive achievements, which spanned the development of the concept to the successful patent application(s); Carcass testing of machine prototypes; And recently, the completion of in vivo testing which will lead to FIM experiments. Despite the long development journey and high financial and technological requirements, Agilis Robotics has consistently achieved its goals.

As the first and only company in Hong Kong To develop robotic tools targeting the ESD and ERBT sectors, Agilis Robotics is well positioned to assist the medical community as the demand for such procedures continues to rise. Already, manual procedures for the target market (digestive system and bladder) in China in 2019 6 million annually The global cases of bladder cancer in 2020 are 573,000[1]. The expected cases suitable for ESD and ERBT robotics procedures number 5.5 million and 690 thousand, respectively, around the world each year. With the worldwide promotion of early screening for colorectal cancer, the number of ESD procedures is rapidly increasing 18.6% per year. By owning unique small diameter surgical robotic instruments that are compatible with both flexible and rigid endoscopes, the company is in an advantageous position to meet the unmet clinical demand for interventional endoscopy and, most importantly, offer patients benefits in terms of shorter procedure time and lower recurrence rate.

Kwok Ka-Wai, Ph.D. (Imp London), co-founder of Agilis Robotics He said, “Under the watchful eye of a professional management team consisting of experts in robotics, clinical trials and finance, with a thorough understanding and experience in research and development, clinical workflow and money management, we will be able to tackle the various aspects of surgical device development. This will also ensure that the same team will benefit from Agilis Robotics fully from the booming market segments and maintain their growth path.”

Jason Y. K. Chan, resident at Johns Hopkins Medicine (DABOto), co-founder of Agilis Robotics He said, “With the increasing popularity of endoscopic procedures, particularly colorectal examination, there is a rapidly increasing unmet need to treat the identified lesions and remove them with minimal surgical intervention. In the bladder, there is a significant unmet need for mass resections to reduce Recurring Bladder Cancer Agilis addresses these needs and enhances the ease and comfort of the surgeon in performing these procedures, with the goal of improving patient care, reducing hospital stays and the need for more invasive procedures.

About Agilis Robotics Limited

Agilis Robotics is a startup that develops highly accurate and flexible robotic instruments for intraluminal surgery. The robotic system is able to integrate seamlessly into the current clinical workflow and significantly reduces the learning curve associated with laparoscopic surgery. Ultimately, Agilis Robotics’ goal is to provide clinicians with the next generation of minimally invasive tools so that more patients can receive effective and efficient early care.

About the co-founders of Agilis Robotics Limited

Drs. Ka Wai Kok He received his Ph.D. Certificate from Hamlin Center for Robotic Surgery, Department of Computing, Imperial College London. He was awarded a Croucher Foundation Fellowship, which supported his research, which was supervised by consultants at The University of GeorgiaBrigham and Women’s Hospital, Harvard Medical School. Dr. Kwok has co-authored over 135 peer-viewed articles and is the principal investigator in the Interventional Imaging Systems and Robotics (IRIS) group at The University of Hong Kong (HKU) with over 5 licensed inventions. Dr. Kwok received the 2015/16 Early Career Awards given by the Research Grants Council (RGC) in Hong KongIROS Toshio Fukuda Young Professional Award in 2020, HKU Award 2019-2020 for Outstanding Young Researcher and HKU Young Innovator Award for 2020.

Dr. Jason Chan Graduated from Guy’s, King’s, and St Thomas’ Medical College London, followed by specialized training in otolaryngology and head and neck surgery at Johns Hopkins Medicine with advanced training in head and neck surgery, microvascular reconstruction and robotics. He is currently an Associate Professor in the Department of Otolaryngology and Head and Neck Surgery at The Chinese University of Hong Kong With research interests, the application of robotics in head and neck surgery recently led the transoral robotic surgery component of the first global application of da Vinci SP in transoral head and neck surgery.

[1] Globalkan 2020International Agency for Research on Cancer

cherry man
[email protected]
+852-2864 4848

Source: Agilis Robotics

#Agilis #Robotics #aims #raise #funds #Phase #completed

Leave a Comment

Your email address will not be published. Required fields are marked *